IQVIA’s latest usage and spending trends report forecasts US obesity market will grow to $35bn by 2028, while the two leading GLP-1 agonists have already posted eye-popping sales growth.

The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing, with an unusually long OS result in the control arm.

Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.

Astellas is building off an existing relationship with the biotech formed last August, joining the growing number of large pharmas looking at tackling solid tumors with cell therapy.

The drug maker said the program would allow for continued reimbursement when patients change insurance plans. A Sangamo-partnered gene therapy for hemophilia A is also in the works.

CEO Daniel O’Day highlighted Gilead’s large pipeline and relative safety from patent expirations over the next few years in the company’s Q1 earnings call.